264 related articles for article (PubMed ID: 27920093)
21. High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma.
Ahmed M; Hussain AR; Bavi P; Ahmed SO; Al Sobhi SS; Al-Dayel F; Uddin S; Al-Kuraya KS
Carcinogenesis; 2014 Jul; 35(7):1564-72. PubMed ID: 24583924
[TBL] [Abstract][Full Text] [Related]
22. Analysis of the roles of glucose transporter 1 and hexokinase 2 in the metabolism of glucose by extrahepatic bile duct cancer cells.
Yoon SO; Jeon TJ; Park JS; Ryu YH; Lee JH; Yoo JS; Kim JK; Yoon DS; Oh EJ
Clin Nucl Med; 2015 Mar; 40(3):e178-82. PubMed ID: 25608150
[TBL] [Abstract][Full Text] [Related]
23. Feasibility of FDG-PET/CT for the initial diagnosis of papillary thyroid cancer.
Kim H; Na KJ; Choi JH; Ahn BC; Ahn D; Sohn JH
Eur Arch Otorhinolaryngol; 2016 Jun; 273(6):1569-76. PubMed ID: 25971994
[TBL] [Abstract][Full Text] [Related]
24. Metformin Promotes 2-Deoxy-2-[
Wang Z; Kang F; Gao Y; Liu Y; Xu X; Ma X; Ma W; Yang W; Wang J
Mol Imaging Biol; 2018 Jun; 20(3):388-397. PubMed ID: 29256045
[TBL] [Abstract][Full Text] [Related]
25. mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib.
Hanly EK; Bednarczyk RB; Tuli NY; Moscatello AL; Halicka HD; Li J; Geliebter J; Darzynkiewicz Z; Tiwari RK
Oncotarget; 2015 Nov; 6(37):39702-13. PubMed ID: 26284586
[TBL] [Abstract][Full Text] [Related]
26. LARP7 in papillary thyroid carcinoma induces NIS expression through suppression of the SHH signaling pathway.
Sui X; Sui Y; Wang Y
Mol Med Rep; 2018 Jun; 17(6):7521-7528. PubMed ID: 29620212
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma.
Choi EK; Chong A; Ha JM; Jung CK; O JH; Kim SH
Clin Endocrinol (Oxf); 2017 Jul; 87(1):73-79. PubMed ID: 28329426
[TBL] [Abstract][Full Text] [Related]
28. Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells.
Klubo-Gwiezdzinska J; Jensen K; Costello J; Patel A; Hoperia V; Bauer A; Burman KD; Wartofsky L; Vasko V
Endocr Relat Cancer; 2012 Jun; 19(3):447-56. PubMed ID: 22389381
[TBL] [Abstract][Full Text] [Related]
29. Metformin--an adjunct antineoplastic therapy--divergently modulates tumor metabolism and proliferation, interfering with early response prediction by 18F-FDG PET imaging.
Habibollahi P; van den Berg NS; Kuruppu D; Loda M; Mahmood U
J Nucl Med; 2013 Feb; 54(2):252-8. PubMed ID: 23376854
[TBL] [Abstract][Full Text] [Related]
30. Iodide- and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer.
Ruan M; Liu M; Dong Q; Chen L
J Clin Endocrinol Metab; 2015 May; 100(5):1771-9. PubMed ID: 25768669
[TBL] [Abstract][Full Text] [Related]
31. Relationship between clinicopathological factors and fluorine-18-fluorodeoxyglucose uptake in patients with papillary thyroid cancer.
Kaida H; Hiromatsu Y; Kurata S; Kawahara A; Hattori S; Taira T; Kobayashi M; Uchida M; Yamada K; Mihashi H; Umeno H; Kage M; Nakashima T; Hayabuchi N; Ishibashi M
Nucl Med Commun; 2011 Aug; 32(8):690-8. PubMed ID: 21606885
[TBL] [Abstract][Full Text] [Related]
32. DT-13 inhibited the proliferation of colorectal cancer via glycolytic metabolism and AMPK/mTOR signaling pathway.
Wei X; Mao T; Li S; He J; Hou X; Li H; Zhan M; Yang X; Li R; Xiao J; Yuan S; Sun L
Phytomedicine; 2019 Feb; 54():120-131. PubMed ID: 30668361
[TBL] [Abstract][Full Text] [Related]
33. SIN1, a critical component of the mTOR-Rictor complex, is overexpressed and associated with AKT activation in medullary and aggressive papillary thyroid carcinomas.
Moraitis D; Karanikou M; Liakou C; Dimas K; Tzimas G; Tseleni-Balafouta S; Patsouris E; Rassidakis GZ; Kouvaraki MA
Surgery; 2014 Dec; 156(6):1542-8; discussion 1548-9. PubMed ID: 25456951
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathologic characteristics of synchronous primary thyroid cancer detected by initial staging 18F-FDG PET-CT examination in patients with underlying malignancy.
Kim BH; Lee CH; Kim SJ; Jeon YK; Kim SS; Kim YK; Kim IJ
Thyroid; 2013 Nov; 23(11):1431-6. PubMed ID: 23510334
[TBL] [Abstract][Full Text] [Related]
35. TMP21 modulates cell growth in papillary thyroid cancer cells by inducing autophagy through activation of the AMPK/mTOR pathway.
Xu X; Gao H; Qin J; He L; Liu W
Int J Clin Exp Pathol; 2015; 8(9):10824-31. PubMed ID: 26617795
[TBL] [Abstract][Full Text] [Related]
36. PTEN regulates plasma membrane expression of glucose transporter 1 and glucose uptake in thyroid cancer cells.
Morani F; Phadngam S; Follo C; Titone R; Aimaretti G; Galetto A; Alabiso O; Isidoro C
J Mol Endocrinol; 2014 Oct; 53(2):247-58. PubMed ID: 25125078
[TBL] [Abstract][Full Text] [Related]
37. Glycolysis-related protein expression in thyroid cancer.
Nahm JH; Kim HM; Koo JS
Tumour Biol; 2017 Mar; 39(3):1010428317695922. PubMed ID: 28347233
[TBL] [Abstract][Full Text] [Related]
38. Has_circ_0008274 promotes cell proliferation and invasion involving AMPK/mTOR signaling pathway in papillary thyroid carcinoma.
Zhou GK; Zhang GY; Yuan ZN; Pei R; Liu DM
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8772-8780. PubMed ID: 30575918
[TBL] [Abstract][Full Text] [Related]
39. HIF-1α/YAP Signaling Rewrites Glucose/Iodine Metabolism Program to Promote Papillary Thyroid Cancer Progression.
Song H; Qiu Z; Wang Y; Xi C; Zhang G; Sun Z; Luo Q; Shen C
Int J Biol Sci; 2023; 19(1):225-241. PubMed ID: 36594102
[No Abstract] [Full Text] [Related]
40. LDOC1 inhibits proliferation and promotes apoptosis by repressing NF-κB activation in papillary thyroid carcinoma.
Zhao S; Wang Q; Li Z; Ma X; Wu L; Ji H; Qin G
J Exp Clin Cancer Res; 2015 Dec; 34():146. PubMed ID: 26637328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
